Aurinia Pharmaceuticals Inc (AUPH) - Net Assets
Based on the latest financial reports, Aurinia Pharmaceuticals Inc (AUPH) has net assets worth $581.33 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($751.59 Million) and total liabilities ($170.26 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check AUPH financial resilience to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $581.33 Million |
| % of Total Assets | 77.35% |
| Annual Growth Rate | N/A |
| 5-Year Change | 21.34% |
| 10-Year Change | 1517.05% |
| Growth Volatility | 115.56 |
Aurinia Pharmaceuticals Inc - Net Assets Trend (1998–2025)
This chart illustrates how Aurinia Pharmaceuticals Inc's net assets have evolved over time, based on quarterly financial data. Also explore Aurinia Pharmaceuticals Inc asset portfolio for the complete picture of this company's asset base.
Annual Net Assets for Aurinia Pharmaceuticals Inc (1998–2025)
The table below shows the annual net assets of Aurinia Pharmaceuticals Inc from 1998 to 2025. For live valuation and market cap data, see Aurinia Pharmaceuticals Inc market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $581.33 Million | +54.00% |
| 2024-12-31 | $377.48 Million | -0.13% |
| 2023-12-31 | $377.95 Million | -6.78% |
| 2022-12-31 | $405.44 Million | -15.37% |
| 2021-12-31 | $479.09 Million | +17.50% |
| 2020-12-31 | $407.75 Million | +36.55% |
| 2019-12-31 | $298.60 Million | +165.25% |
| 2018-12-31 | $112.58 Million | -32.08% |
| 2017-12-31 | $165.74 Million | +361.04% |
| 2016-12-31 | $35.95 Million | +80.08% |
| 2015-12-31 | $19.96 Million | -55.74% |
| 2014-12-31 | $45.11 Million | +239.13% |
| 2013-12-31 | $13.30 Million | +727.69% |
| 2012-12-31 | $-2.12 Million | -133.05% |
| 2011-12-31 | $6.41 Million | +1.00% |
| 2010-12-31 | $6.35 Million | +32.02% |
| 2009-12-31 | $4.81 Million | -38.90% |
| 2008-12-31 | $7.87 Million | -72.30% |
| 2007-12-31 | $28.41 Million | +40.90% |
| 2006-12-31 | $20.17 Million | -52.39% |
| 2005-12-31 | $42.36 Million | -18.85% |
| 2004-12-31 | $52.20 Million | -23.84% |
| 2003-12-31 | $68.54 Million | +44.12% |
| 2002-12-31 | $47.56 Million | +34.79% |
| 2001-12-31 | $35.28 Million | +176.54% |
| 2000-12-31 | $12.76 Million | +299.74% |
| 1999-12-31 | $3.19 Million | +477.12% |
| 1998-12-31 | $-846.35K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Aurinia Pharmaceuticals Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 64389925000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $1.12 Billion | 192.67% |
| Other Comprehensive Income | $-599.00K | -0.10% |
| Other Components | $111.26 Million | 19.14% |
| Total Equity | $581.33 Million | 100.00% |
Aurinia Pharmaceuticals Inc Competitors by Market Cap
The table below lists competitors of Aurinia Pharmaceuticals Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Global Net Lease, Inc.
NYSE:GNL
|
$2.04 Billion |
|
Sigdo Koppers
SN:SK
|
$2.04 Billion |
|
China Nonferrous Metal Industry’s Foreign Engineering and Construction Co Ltd
SHE:000758
|
$2.04 Billion |
|
Kunshan Kersen Science & Tech
SHG:603626
|
$2.04 Billion |
|
Shenzhen iN-Cube Automation Co. Ltd.
SHE:301312
|
$2.04 Billion |
|
Vohringer Home Technology Co Ltd
SHG:603226
|
$2.04 Billion |
|
JOYY Inc
NASDAQ:JOYY
|
$2.04 Billion |
|
ARMOUR Residential REIT Inc
NYSE:ARR
|
$2.04 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Aurinia Pharmaceuticals Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 377,478,000 to 581,331,000, a change of 203,853,000 (54.0%).
- Net income of 287,202,000 contributed positively to equity growth.
- Share repurchases of 98,156,000 reduced equity.
- Other comprehensive income increased equity by 48,000.
- Other factors increased equity by 14,759,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $287.20 Million | +49.4% |
| Share Repurchases | $98.16 Million | -16.88% |
| Other Comprehensive Income | $48.00K | +0.01% |
| Other Changes | $14.76 Million | +2.54% |
| Total Change | $- | 54.00% |
Book Value vs Market Value Analysis
This analysis compares Aurinia Pharmaceuticals Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.66x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1998-12-31 | $-1.74 | $15.35 | x |
| 1999-12-31 | $5.88 | $15.35 | x |
| 2000-12-31 | $17.03 | $15.35 | x |
| 2001-12-31 | $34.42 | $15.35 | x |
| 2002-12-31 | $36.90 | $15.35 | x |
| 2003-12-31 | $48.72 | $15.35 | x |
| 2004-12-31 | $34.61 | $15.35 | x |
| 2005-12-31 | $26.79 | $15.35 | x |
| 2006-12-31 | $11.97 | $15.35 | x |
| 2007-12-31 | $13.73 | $15.35 | x |
| 2008-12-31 | $3.70 | $15.35 | x |
| 2009-12-31 | $2.01 | $15.35 | x |
| 2010-12-31 | $2.49 | $15.35 | x |
| 2011-12-31 | $1.85 | $15.35 | x |
| 2012-12-31 | $-0.60 | $15.35 | x |
| 2013-12-31 | $2.10 | $15.35 | x |
| 2014-12-31 | $1.55 | $15.35 | x |
| 2015-12-31 | $0.62 | $15.35 | x |
| 2016-12-31 | $1.02 | $15.35 | x |
| 2017-12-31 | $2.15 | $15.35 | x |
| 2018-12-31 | $1.33 | $15.35 | x |
| 2019-12-31 | $3.21 | $15.35 | x |
| 2020-12-31 | $3.44 | $15.35 | x |
| 2021-12-31 | $3.70 | $15.35 | x |
| 2022-12-31 | $2.86 | $15.35 | x |
| 2023-12-31 | $2.64 | $15.35 | x |
| 2024-12-31 | $2.58 | $15.35 | x |
| 2025-12-31 | $4.19 | $15.35 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Aurinia Pharmaceuticals Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 49.40%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 101.47%
- • Asset Turnover: 0.38x
- • Equity Multiplier: 1.29x
- Recent ROE (49.40%) is above the historical average (-47.59%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1998 | 0.00% | -283.33% | 0.50x | 0.00x | $-2.13 Million |
| 1999 | -38.30% | -90.00% | 0.33x | 1.30x | $-1.54 Million |
| 2000 | -49.26% | -696.18% | 0.06x | 1.09x | $-7.56 Million |
| 2001 | -20.99% | -139.78% | 0.14x | 1.05x | $-10.93 Million |
| 2002 | -0.77% | -3.07% | 0.24x | 1.07x | $-5.12 Million |
| 2003 | -21.37% | -191.17% | 0.10x | 1.09x | $-21.50 Million |
| 2004 | -43.22% | -1771.39% | 0.02x | 1.17x | $-27.78 Million |
| 2005 | -68.64% | -2468.42% | 0.02x | 1.28x | $-33.31 Million |
| 2006 | -113.32% | -648.73% | 0.11x | 1.52x | $-24.87 Million |
| 2007 | -119.03% | -1448.70% | 0.05x | 1.50x | $-36.66 Million |
| 2008 | -201.80% | -409.67% | 0.15x | 3.39x | $-16.67 Million |
| 2009 | -158.01% | -187.51% | 0.42x | 1.99x | $-8.08 Million |
| 2010 | -57.66% | -107.02% | 0.33x | 1.62x | $-4.30 Million |
| 2011 | -37.55% | -259.56% | 0.06x | 2.23x | $-3.05 Million |
| 2012 | 0.00% | -158.13% | 1.48x | 0.00x | $-9.53 Million |
| 2013 | -19.14% | -268.42% | 0.04x | 1.74x | $-3.88 Million |
| 2014 | -36.91% | -5988.13% | 0.01x | 1.16x | $-21.16 Million |
| 2015 | -93.21% | -7917.87% | 0.01x | 1.68x | $-20.60 Million |
| 2016 | -64.80% | -13465.32% | 0.00x | 1.59x | $-26.89 Million |
| 2017 | -42.71% | -16855.24% | 0.00x | 1.15x | $-87.37 Million |
| 2018 | -56.96% | -13848.81% | 0.00x | 1.30x | $-75.38 Million |
| 2019 | -29.60% | -27794.03% | 0.00x | 1.09x | $-118.25 Million |
| 2020 | -25.18% | -204.88% | 0.11x | 1.14x | $-143.46 Million |
| 2021 | -37.77% | -396.81% | 0.08x | 1.13x | $-228.88 Million |
| 2022 | -26.68% | -80.71% | 0.28x | 1.16x | $-148.72 Million |
| 2023 | -20.64% | -44.45% | 0.32x | 1.45x | $-115.82 Million |
| 2024 | 1.52% | 2.45% | 0.43x | 1.46x | $-32.00 Million |
| 2025 | 49.40% | 101.47% | 0.38x | 1.29x | $229.07 Million |
Industry Comparison
This section compares Aurinia Pharmaceuticals Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $248,191,134
- Average return on equity (ROE) among peers: -119.98%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Aurinia Pharmaceuticals Inc (AUPH) | $581.33 Million | 0.00% | 0.29x | $2.04 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $1.15 Billion | -12.70% | 0.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $134.04 Million | -42.28% | 0.30x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $-14.95 Million | 0.00% | 0.00x | $448.19K |
| Absci Corp (ABSI) | $274.41 Million | -38.23% | 0.17x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $169.44 Million | -45.00% | 0.21x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $8.87 Million | -144.74% | 0.54x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $7.19 Million | -844.90% | 9.51x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $518.41 Million | -52.35% | 0.08x | $3.74 Billion |
About Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. It also develops aritinercept, a dual inhibitor of B cell-activating factor and … Read more